CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 6 incoming connections
- ScaleRevenue is $1.57B, above the global median of $520.53M
- PositionP/E ratio is 53.72×, higher than 95% of its Pharmaceutical Retailers peers (median 21.34×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.34%
Annual Rate
CNY 0.05Paid unknown
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
Jun 3, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.31BCNY787.95M · vs all stocks (USD)
Trailing P/E
53.72xvs Pharmaceutical Retailers peers
Revenue (TTM)
10.55BCNY1.57B · vs all stocks (USD)
Profit Margin
0.94%vs Pharmaceutical Retailers peers
Beta
0.4240xvs all stocks
52-Week Change
3.70%vs all stocks
Forward Annual Dividend Yield
0.34%vs all stocks
Market Capitalization
5.31BCNY787.95M · vs all stocks (USD)
Enterprise Value
7.44BCNY1.10B · vs all stocks (USD)
Trailing P/E
53.72xvs Pharmaceutical Retailers peers
Price to Sales (TTM)
0.5163xvs Pharmaceutical Retailers peers
Price to Book (MRQ)
2.54xvs Pharmaceutical Retailers peers
Enterprise to Revenue
0.7050xvs Pharmaceutical Retailers peers
Enterprise to EBITDA
31.63xvs Pharmaceutical Retailers peers
Gross Margin
25.94%vs Pharmaceutical Retailers peers
Profit Margin
0.94%vs Pharmaceutical Retailers peers
Operating Margin
1.97%vs Pharmaceutical Retailers peers
Return on Assets (TTM)
1.23%vs Pharmaceutical Retailers peers
Return on Equity (TTM)
4.67%vs Pharmaceutical Retailers peers
Revenue (TTM)
10.55BCNY1.57B · vs all stocks (USD)
Revenue per Share (TTM)
27.22CNYUpdated Aug 20, 2026Quarterly Revenue Growth
9.40%vs Pharmaceutical Retailers peers
Gross Profit (TTM)
2.75BCNY408.58M · vs all stocks (USD)
EBITDA (TTM)
238.90MCNY35.48M · vs all stocks (USD)
Net Income (TTM)
98.97MCNY14.70M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-59.60%vs Pharmaceutical Retailers peers
Operating Cash Flow (TTM)
769.11MCNY114.23M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.12BCNY166.42M · vs all stocks (USD)
Forward Annual Dividend Rate
0.0500CNYUpdated Aug 20, 2026Forward Annual Dividend Yield
0.34%vs all stocks
Trailing Annual Dividend Rate
0.0450CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.34%vs all stocks
Payout Ratio
0.00%vs Pharmaceutical Retailers peers
Minority Interest (Equity)
162.55MCNYFY2025 · Dec 31, 2025Revenue
10.33BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
7.63BCNYFY2025 · Dec 31, 2025Gross Profit
2.70BCNYFY2025 · Dec 31, 2025Operating Income
223.90MCNY33.25M · vs all stocks (USD)
Pre-tax Income
171.73MCNYFY2025 · Dec 31, 2025Income Tax Expense
54.82MCNYFY2025 · Dec 31, 2025Net Income
116.91MCNYFY2025 · Dec 31, 2025EBIT
298.64MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
615.18MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
385.85MCNYFY2025 · Dec 31, 2025Other Operating Expenses
58.75MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
10.24MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
126.91MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.2800CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.2800CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
407.97MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
407.97MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
116.91MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-2.68MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
191.94MCNYFY2025 · Dec 31, 2025Free Cash Flow
20.31MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
395.22MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
116.91MCNYFY2025 · Dec 31, 2025Other Non-cash Items
148.88MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-219.04MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
145.19MCNYFY2025 · Dec 31, 2025Capital Expenditures
-171.63MCNYFY2025 · Dec 31, 2025Net Acquisitions
-460.32MCNYFY2025 · Dec 31, 2025Purchase of Investments
-14.29MCNYFY2025 · Dec 31, 2025Sale of Investments
26.77MCNYFY2025 · Dec 31, 2025Other Investing Activity
-34.88MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-654.35MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.31BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.75BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-90.27MCNYFY2025 · Dec 31, 2025Other Financing Charges
-32.48MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-559.02MCNYFY2025 · Dec 31, 2025Shares Outstanding
405.61MSharesUpdated Aug 20, 2026Float Shares
108.46MSharesUpdated Aug 20, 2026% Held by Insiders
75.24%vs all stocks
% Held by Institutions
0.12%vs all stocks
Total Cash (MRQ)
1.46BCNY217.19M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.60CNYUpdated Aug 20, 2026Total Debt (MRQ)
3.44BCNY510.22M · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.49xvs Pharmaceutical Retailers peers
Current Ratio (MRQ)
0.9200xvs Pharmaceutical Retailers peers
Book Value per Share (MRQ)
5.29CNYUpdated Aug 20, 2026Total Assets
9.41BCNY1.40B · vs all stocks (USD)
Total Current Assets
5.02BCNYFY2025 · Dec 31, 2025Total Liabilities
7.11BCNYFY2025 · Dec 31, 2025Total Non-current Assets
4.39BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.57BCNYFY2025 · Dec 31, 2025Total Current Liabilities
5.55BCNYFY2025 · Dec 31, 2025Cash
395.22MCNYFY2025 · Dec 31, 2025Cash Equivalents
845.38MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.24BCNYFY2025 · Dec 31, 2025Accounts Receivable
1.06BCNYFY2025 · Dec 31, 2025Inventory
1.89BCNYFY2025 · Dec 31, 2025Accounts Payable
3.15BCNYFY2025 · Dec 31, 2025Short-term Debt
1.63BCNYFY2025 · Dec 31, 2025Other Current Liabilities
270.88MCNYFY2025 · Dec 31, 2025Long-term Debt
1.44BCNYFY2025 · Dec 31, 2025Common Stock (Book)
405.36MCNYFY2025 · Dec 31, 2025Retained Earnings
738.64MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.29BCNY340.62M · vs all stocks (USD)
52-Week Low
10.52CNYUpdated Aug 20, 202652-Week High
23.01CNYUpdated Aug 20, 202652-Week Change
3.70%vs all stocks
Beta
0.4240xvs all stocks
50-Day MA
13.28CNYUpdated Aug 20, 2026200-Day MA
14.64CNYUpdated Aug 20, 2026Avg 10-Day Volume
11.95MSharesUpdated Aug 20, 2026Avg 30-Day Volume
9.84MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.2500CNYUpdated Aug 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
Elevated ROE With High Debt-to-Equity and Equity Multiplier
Return on equity reads high on a balance sheet carrying a lot of debt against that equity.
Reads
Where is this company structurally exposed?
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
P/E ratio is 53.72×, higher than 95% of its Pharmaceutical Retailers peers (median 21.34×)Significant
P/E ratio: 53.72Industry median: 21.34Industry P95: 41.99Peers compared: 22.00
Financial Health
Altman Z-Score 1.69: grey zoneSignificant
Altman Z-Score: 1.69
Low earnings qualitySignificant
Earnings Quality Score: -2.25
Supply Chain
Midstream position: 5 outgoing, 6 incoming connectionsNotable
Outgoing: 5.00Incoming: 6.00
High connectivity hub: 11 industry connectionsNotable
Total Connections: 11.00
Scale
Revenue is $1.57B, above the global median of $520.53MNotable
Revenue (USD): 1,566,892,786.77Global Median: 520,528,949.311
Levered free cash flow is $166.42M, above the global median of $16.24MNotable
Levered free cash flow (USD): 166,415,913.836Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Dogus Otomotiv Servis ve Ticaret A.S.
Tier 1FlowUnit ReplicationInterfaceRisk
Idom Inc.
Tier 1FlowUnit ReplicationInterfaceRisk
Carrefoursa Carrefour Sabanci Ticaret Merkezi A.S.
Tier 1FlowUnit ReplicationInterfaceProduction
Hunan Heshun Petroleum Co., Ltd.
Tier 1FlowUnit ReplicationInterfaceProduction
Petco Health and Wellness Company, Inc.
Tier 1FlowUnit ReplicationInterfaceRisk
Natural Grocers by Vitamin Cottage, Inc.
Tier 1FlowUnit ReplicationInterfaceAttention
V2 Retail Ltd.
Tier 1FlowUnit ReplicationRiskInterface
Shanghai Waigaoqiao Free Trade Zone Development Co. Ltd.
Tier 1FlowUnit ReplicationProductionInterface
WH Smith plc
Tier 1FlowUnit ReplicationAttentionInterface
Sanjiang Shopping Club Co., Ltd.
Tier 1FlowUnit ReplicationInterfaceProduction
Companies that share active interpretations — structural patterns currently present in both stocks.
Avery Dennison Corporation
2 interpretationsElevated ROE With High Debt-to-Equity and Equity MultiplierElevated Leverage on Three Denominators
The Clorox Company
2 interpretationsElevated ROE With High Debt-to-Equity and Equity MultiplierElevated Leverage on Three Denominators
Cinemark Holdings Inc.
2 interpretationsElevated ROE With High Debt-to-Equity and Equity MultiplierElevated Leverage on Three Denominators